

Simon Weonsang Ro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8228320/publications.pdf>

Version: 2024-02-01

29
papers

726
citations

686830

13
h-index

552369

26
g-index

29
all docs

29
docs citations

29
times ranked

1144
citing authors

#	ARTICLE	IF	CITATIONS
1	MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3026.	1.7	104
2	Barrier to autointegration factor 1, procollagen α 1(I) lysine, 2 α 1(I) oxoglutarate 5 α dioxygenase 3, and splicing factor 3b subunit 4 as early β 1 stage cancer decision markers and drivers of hepatocellular carcinoma. <i>Hepatology</i> , 2018, 67, 1360-1377.	3.6	90
3	Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model. <i>Journal of Hepatology</i> , 2016, 64, 618-627.	1.8	88
4	Transforming Growth Factor- β 2 Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail. <i>Gastroenterology</i> , 2017, 153, 1378-1391.e6.	0.6	71
5	Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4691-4696.	3.3	56
6	High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2019, 20, 581.	1.8	35
7	Investigation of Oncogenic Cooperation in Simple Liver-Specific Transgenic Mouse Models Using Noninvasive In Vivo Imaging. <i>PLoS ONE</i> , 2013, 8, e59869.	1.1	32
8	Inhibition of tumour angiogenesis and growth by small hairpin siRNA and siRNA in hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 632-642.	1.9	27
9	Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti β 1 cancer therapy. <i>International Journal of Cancer</i> , 2016, 138, 1601-1608.	2.3	26
10	Genetically Engineered Mouse Models for Liver Cancer. <i>Cancers</i> , 2020, 12, 14.	1.7	23
11	YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. <i>Hepatology</i> , 2021, 74, 2605-2621.	3.6	22
12	Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. <i>BMC Gastroenterology</i> , 2016, 16, 13.	0.8	16
13	c-Myc-driven Hepatocarcinogenesis. <i>Anticancer Research</i> , 2021, 41, 4937-4946.	0.5	14
14	Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 249-258.	1.9	13
15	Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 1481-1491.	2.2	12
16	Synergic chemoprevention with dietary carbohydrate restriction and supplementation of AMPK-activating phytochemicals. <i>European Journal of Cancer Prevention</i> , 2016, 25, 54-64.	0.6	11
17	Comparison of liver oncogenic potential among human RAS isoforms. <i>Oncotarget</i> , 2016, 7, 7354-7366.	0.8	11
18	Transgenic mouse model expressing P53R172H, luciferase, EGFP and KRASG12D in a single open reading frame for live imaging of tumor. <i>Scientific Reports</i> , 2015, 5, 8053.	1.6	10

#	ARTICLE	IF	CITATIONS
19	Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. BMC Cancer, 2022, 22, 423.	1.1	10
20	Sleeping Beauty transposon system harboring HRAS, c-Myc and shp53 induces sarcomatoid carcinomas in mouse skin. Oncology Reports, 2013, 29, 1293-1298.	1.2	8
21	Analysis of miRNA expression patterns in human and mouse hepatocellular carcinoma cells. Hepatology Research, 2015, 45, 1331-1340.	1.8	7
22	Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer. Translational Oncology, 2021, 14, 101158.	1.7	7
23	Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS). Cancers, 2022, 14, 2733.	1.7	7
24	Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2015, 76, 257-267.	1.1	5
25	Pro-tumorigenic roles of TGF- β 2 signaling during the early stages of liver tumorigenesis through upregulation of Snail. BMB Reports, 2017, 50, 599-600.	1.1	5
26	Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. Biology, 2022, 11, 585.	1.3	5
27	Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma. Journal of Liver Cancer, 2021, 21, 1-11.	0.3	4
28	Pharmacological Inhibition of Sonic Hedgehog Signaling Suppresses Tumor Development in a Murine Model of Intrahepatic Cholangiocarcinoma. International Journal of Molecular Sciences, 2021, 22, 13214.	1.8	4
29	Making cancer fat: reprogramming of lipid metabolism by CD147 in hepatocellular carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 380-382.	0.7	3